The use of a new antituberculosis drug-thianide (1314 Th)-in conjunction with streptomycin or phthivazid
Chemotherapeutic activity of thianide (1314 Th) in combination with streptomycin or phthivazid was studied on a model of hematogenic tuberculosis of white mice. In experimental infection of mice with mycobacteria B, bovinus 8 a daily dose of 0.65 mg per mouse of thianide alone proved to be therapeutically ineffective. Combined administration of thianide and streptomycin, or thianide and phthivazid led to potentiated chemotherapeutic activity of both preparations, giving a positive therapeutic effect. These data permit a three-fold reduction of the daily therapeutic dose of thianide and streptomycin. In infecting the animals with mycobacteria tuberculosis H37Rv (of the human type), causing severe hematogenic tuberculosis in mice, combined use of thianide (1.3 mg) and streptomycin (800 units), or thianide (of 1.3 mg) and phthivazid (0.6 mg) also led to intensified chemotherapeutic activity of both preparations. These preparations may be used in the treatment of tuberculosis in man.
KeywordsPublic Health Tuberculosis Streptomycin Therapeutic Effect Mycobacterium Tuberculosis
Unable to display preview. Download preview PDF.
- 1.N. F. Kucherova, R. M. Khomutov, E. I. Budovskii, et al., Zh. Obshchei Khimii (1959), No. 3, p. 915.Google Scholar